Lavipharm Financials
| LAVI Stock | EUR 0.85 0.03 3.41% |
Lavipharm |
Please note, the imprecision that can be found in Lavipharm's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Lavipharm SA. Check Lavipharm's Beneish M Score to see the likelihood of Lavipharm's management manipulating its earnings.
Lavipharm Stock Summary
Lavipharm competes with Intertech, Foodlink, Intracom Constructions, Daios Plastics, and Attica Bank. Lavipharm S.A. develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products in Greece and internationally. Lavipharm S.A. was founded in 1911 and is based in Paiania, Greece. LAVIPHARM operates under Drug Manufacturers - Major classification in Greece and is traded on Athens Stock Exchange.| Instrument | Greece Stock View All |
| Exchange | Athens Exchange |
| ISIN | GRS246073001 |
| Business Address | Agias Marinas Street, |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Major |
| Benchmark | Dow Jones Industrial |
| Website | www.lavipharm.gr |
| Phone | 30 210 66 91 000 |
| Currency | EUR - Euro |
You should never invest in Lavipharm without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Lavipharm Stock, because this is throwing your money away. Analyzing the key information contained in Lavipharm's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Lavipharm Key Financial Ratios
Lavipharm's financial ratios allow both analysts and investors to convert raw data from Lavipharm's financial statements into concise, actionable information that can be used to evaluate the performance of Lavipharm over time and compare it to other companies across industries.| Return On Asset | 0.0403 | |||
| Beta | 0.66 | |||
| Z Score | -2.8 |
Lavipharm Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Lavipharm's current stock value. Our valuation model uses many indicators to compare Lavipharm value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lavipharm competition to find correlations between indicators driving Lavipharm's intrinsic value. More Info.Lavipharm SA is currently regarded as number one stock in return on asset category among its peers. It also is currently regarded as number one stock in profit margin category among its peers fabricating about 0.62 of Profit Margin per Return On Asset. The ratio of Return On Asset to Profit Margin for Lavipharm SA is roughly 1.63 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lavipharm's earnings, one of the primary drivers of an investment's value.Lavipharm SA Systematic Risk
Lavipharm's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Lavipharm volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Lavipharm SA correlated with the market. If Beta is less than 0 Lavipharm generally moves in the opposite direction as compared to the market. If Lavipharm Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Lavipharm SA is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Lavipharm is generally in the same direction as the market. If Beta > 1 Lavipharm moves generally in the same direction as, but more than the movement of the benchmark.
Lavipharm March 20, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Lavipharm help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Lavipharm SA. We use our internally-developed statistical techniques to arrive at the intrinsic value of Lavipharm SA based on widely used predictive technical indicators. In general, we focus on analyzing Lavipharm Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Lavipharm's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.64 | |||
| Information Ratio | 0.1726 | |||
| Maximum Drawdown | 11.9 | |||
| Value At Risk | (2.50) | |||
| Potential Upside | 2.7 |
Additional Tools for Lavipharm Stock Analysis
When running Lavipharm's price analysis, check to measure Lavipharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lavipharm is operating at the current time. Most of Lavipharm's value examination focuses on studying past and present price action to predict the probability of Lavipharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lavipharm's price. Additionally, you may evaluate how the addition of Lavipharm to your portfolios can decrease your overall portfolio volatility.